You can't just blindly look at the drug pipeline chart.
There's far more to the story than meets the eye, which will get pitched to US heavy weight investors.
If the US IPO is oversubscribed (very high probability), we will know what these US heavy weight investors think our our drug program(s)!
By the looks of it, the NASDAQ listing could be any day now.
After we list (reading the 3rd Form F-1/A submission), it seems we have the following news that will drop to drive the share price and keep punters interested/speculating for months:
- OSA results (due Q4 2021)
- TBI results (pre-clinical), supported by the US NFL. As we know, NFL is huge in the states and will likely be a big drawing card/media card to excite the market. TBI could be huge and is really a sleeping giant.
- Any news on the second psychedelics program (perhaps this results to the pending patent (AU 2021902426 A method of treatment). There's already a provisional patent (Australia) for Psi-GAD/Methods for the treatment of generalized anxiety disorder (GAD). The pending patent sounds similar and that's why we think it relates to a potential second psychedelics program.
On top of these three newsworthy events, early next year should be a block buster for progress looking at the drug pipeline chart. It's clinical trials (i.e. GAD psychedelics etc) + Pre-IND+ IND galore. That will set us up for a big second half of next year, with multiple back to back FDA-approved phase two trials.
If you read the 3rd Form F-1/A submission in detail, OSA, TBI, and IHL-675A are
ALL heading straight to phase 2 FDA trials. Indeed they all seem to be skipping phase 1 FDA trials, considering the current work done at the pre-clinical and clinical level in Australia. Furthermore, there's significant known safety studies behind CBD to aid our FDA submission.
That's the reason why we wrote in the last blog post on the Trading For Millions website that the share price could hit $1 in the second half of next year --- at the latest.
Mind you, it might be sooner...
TBH, we've always being totally wrong about IHL since 1-2 cents per share.
The share price has
always exceeded our expectations!
On a constructive note, it's interesting why they didn't say 'Pre-IND Q3 2022' for IHL-675A for ILD, similar to IBD & RA. Perhaps that's because they haven't formally received the patent yet? (someone correct us if wrong). But in the latest quarterly, the company wrote: "
Pleasingly, the International Examiner considers that claims directed to IHL-675A and methods for the treatment of inflammatory conditions using IHL-675A are novel and inventive and meet the requirements for industrial applicability. Based on the International Search Report and Opinion. IHL is currently considering
options to expedite the filing and examination of patent applications in key jurisdictions as part of IHL’s intellectual property (IP) strategy."
So it could be just a matter of time?
Nevertheless, the most important questions we need answered at this stage of the game: will the US IPO be over or under subscribed and what price will the raising be at?
In the last TFM blog post, we suggested it would be oversubscribed and done at a premium for many reasons highlighted in the post. Most importantly, as others have pointed out here, we have Roth and Sugar in our corner and they are the dream team! Historically, IPO's that are oversubscribed tend to do well.
FYI, AHI's IPO was undersubscribed and we saw what happened.
Exciting times ahead!
To your first million,
-Trading For Millions.
